Background and Objectives: The treatment of end-stage ankle osteoarthritis (OA) and associated hindfoot deformities remains a major challenge for orthopedic surgeons. Numerous techniques and surgical approaches have been proposed for tibiotalar (TT) and tibiotalocalcaneal (TTC) arthrodesis, from arthroscopic to open, as well as numerous devices proposed for internal fixation (retrograde intramedullary nails, cannulated screws, and plating systems). The aim of this study was to retrospectively analyze the results, with at least 18 months of follow-up, with SilverbackTM TT/TTC Plating System Paragon28 in a group of 20 patients with severe OA and hindfoot deformities (mainly secondary post-traumatic OA). Materials and Methods: The demographic characteristics and past medical history of the patients were collected and analyzed to identify the cause of the pathology. The degree of OA and deformity were quantified based on foot and ankle weight-bearing radiography and CT examination. Pre- and post-operative clinical and functional scores (ROM, VAS, AOFAS, FFI, and SF-36) and radiographic parameters (anterior distal tibial angle, tibiotalar angle, coronal tibiotalar angle, and hindfoot alignment angle) were evaluated. Results: All of the patients showed clinical and radiographic fusion at an average of 14 weeks (range 12–48), with improvement in pain and functional scores, without major surgical complications and/or infections. Conclusions: Despite the limitations of our study, the results with this new plating system showed good results in terms of bone consolidation, post-operative complications, and improvement of pain and quality of life in patients with severe OA and deformities of the ankle and hindfoot.

Adverse Reaction to Metal Debris (ARMD) is one of the most frequent complications after Total Hip Replacement (THR) and often a cause of surgical revision. This is true especially for implants with Metal-on-Metal (MoM) and Large Diameter Heads (LDHs), which are frequently used to improve stability and reduce the risk of dislocation. However, ARMD is not exclusive to MoM replacement, as it can also occur in other implants such Ceramic-on-Ceramic (CoC), Metal-on-Polyethylene (MoP), and Ceramic-on-Polyethylene (CoP). In these non-MoM implants, ARMD is not caused by the tribo-corrosion between bearing surfaces but, rather, by the fretting at the interface between neck and stem of dissimilar metals. A case of a severe ARMD that happened to a 73-year-old female patient with CoC bearing THR at the right hip is presented in this case report. In this case, the ARMD was misdiagnosed for over a year, resulting in the development of a massive pseudotumor. The treatment of choice was a two-stage revision with the implant of a hip megaprosthesis. After more than 2 years of follow-up, complete recovery of hip Range of Motion (ROM) and normalization of chromium and cobalt levels in blood and urine were achieved. Despite the relatively short follow-up period, this can be considered a successful treatment of a major and misdiagnosed ARMD in a non-MoM hip replacement.

Charcot Foot (CF), part of a broader condition known as Charcot Neuro-Osteoarthropathy (CNO), is characterized by neuropathic arthropathy with a progressive alteration of the foot. CNO is one of the most devastating complications in patients with diabetes mellitus and peripheral neuropathy but can also be caused by neurological or infectious diseases. The pathogenesis is multifactorial; many studies have demonstrated the central role of inflammation and the Receptor Activator of NF-κB ligand (RANKL)-Receptor Activator of NF-κB (RANK)-Osteoprotegerin (OPG) pathway in the acute phase of the disease, resulting in the serum overexpression of RANKL. This overexpression and activation of this signal lead to increased osteoclast activity and osteolysis, which is a prelude to bone destruction. The aim of this narrative review is to analyze this signaling pathway in bone remodeling, and in CF in particular, to highlight its clinical aspects and possible therapeutic implications of targeting drugs at different levels of the pathway. Drugs that act at different levels in this pathway are anti-RANKL monoclonal antibodies (Denosumab), bisphosphonates (BP), and calcitonin. The literature review showed encouraging data on treatment with Denosumab, although in a few studies and in small sample sizes. In contrast, BPs have been re-evaluated in recent years in relation to the high possibility of side effects, while calcitonin has shown little efficacy on CNO.